KR102446636B1 - 인간 보체 c5에 결합하는 안정한 폴리펩티드 - Google Patents

인간 보체 c5에 결합하는 안정한 폴리펩티드 Download PDF

Info

Publication number
KR102446636B1
KR102446636B1 KR1020167007498A KR20167007498A KR102446636B1 KR 102446636 B1 KR102446636 B1 KR 102446636B1 KR 1020167007498 A KR1020167007498 A KR 1020167007498A KR 20167007498 A KR20167007498 A KR 20167007498A KR 102446636 B1 KR102446636 B1 KR 102446636B1
Authority
KR
South Korea
Prior art keywords
leu
asp
glu
ala
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167007498A
Other languages
English (en)
Korean (ko)
Other versions
KR20160048121A (ko
Inventor
요아킴 닐손
에릭 노들링
파트릭 스트룀베리
Original Assignee
스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) filed Critical 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘)
Publication of KR20160048121A publication Critical patent/KR20160048121A/ko
Application granted granted Critical
Publication of KR102446636B1 publication Critical patent/KR102446636B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
KR1020167007498A 2013-08-28 2014-08-28 인간 보체 c5에 결합하는 안정한 폴리펩티드 Active KR102446636B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1350986-4 2013-08-28
SE1350986 2013-08-28
PCT/EP2014/068282 WO2015028558A1 (en) 2013-08-28 2014-08-28 Stable polypeptides binding to human complement c5

Publications (2)

Publication Number Publication Date
KR20160048121A KR20160048121A (ko) 2016-05-03
KR102446636B1 true KR102446636B1 (ko) 2022-09-23

Family

ID=51539238

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167007498A Active KR102446636B1 (ko) 2013-08-28 2014-08-28 인간 보체 c5에 결합하는 안정한 폴리펩티드

Country Status (29)

Country Link
US (1) US9994626B2 (enExample)
EP (2) EP3038633B1 (enExample)
JP (2) JP6767865B2 (enExample)
KR (1) KR102446636B1 (enExample)
CN (1) CN105658228B (enExample)
AU (1) AU2014314222B2 (enExample)
BR (1) BR112016003142A2 (enExample)
CA (1) CA2926976C (enExample)
CY (1) CY1123732T1 (enExample)
DK (1) DK3038633T3 (enExample)
ES (1) ES2842105T3 (enExample)
HR (1) HRP20210013T1 (enExample)
HU (1) HUE052613T2 (enExample)
IL (1) IL244218A (enExample)
LT (1) LT3038633T (enExample)
MX (1) MX382140B (enExample)
MY (1) MY173804A (enExample)
NZ (1) NZ718153A (enExample)
PH (1) PH12016500371B1 (enExample)
PL (1) PL3038633T3 (enExample)
PT (1) PT3038633T (enExample)
RS (1) RS61347B1 (enExample)
RU (2) RU2020128977A (enExample)
SA (1) SA516370622B1 (enExample)
SG (1) SG11201602679VA (enExample)
SI (1) SI3038633T1 (enExample)
SM (1) SMT202100006T1 (enExample)
UA (1) UA117933C2 (enExample)
WO (1) WO2015028558A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58503B1 (sr) 2012-02-20 2019-04-30 Swedish Orphan Biovitrum Ab Publ Polipeptidi koji se vezuju za humani komplement c5
MX367423B (es) * 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
LT3038633T (lt) * 2013-08-28 2021-03-25 Ipc Research, Llc Stabilūs polipeptidai, kurie rišasi prie žmogaus komplemento c5
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
CN117327188A (zh) 2017-07-11 2024-01-02 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
WO2022171892A1 (en) * 2021-02-15 2022-08-18 Affibody Ab New her2-binding polypeptide
KR20240134857A (ko) * 2021-11-01 2024-09-10 아이피씨 리써치, 엘엘씨 C5-결합 단백질 투여
WO2024227886A1 (en) 2023-05-02 2024-11-07 Mebrahtu Aman Bispecific binding molecule

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015819A1 (en) 2001-08-17 2003-02-27 Tanox, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b
WO2007028968A1 (en) 2005-09-09 2007-03-15 Evolutec Limited Method of treating myasthenia gravis
WO2007106585A1 (en) 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
CA2424379C (en) 2000-10-10 2013-10-01 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
EP1667702A2 (en) 2003-09-10 2006-06-14 Baxter International Inc., Baxter Healthcare Corp. Peptides that inhibit complement activation
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
DK1991275T3 (en) * 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
US8937153B2 (en) 2007-07-31 2015-01-20 Affibody Ab Compositions, methods and uses
DK2231860T3 (da) * 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
MX2011001371A (es) 2008-08-05 2011-06-16 Novartis Ag Composiciones y metodos para anticuerpos que se dirigen a la proteina de complementos c5.
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
WO2012004384A2 (en) 2010-07-09 2012-01-12 Affibody Ab Polypeptides
RS58503B1 (sr) * 2012-02-20 2019-04-30 Swedish Orphan Biovitrum Ab Publ Polipeptidi koji se vezuju za humani komplement c5
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
EP2935335B1 (en) 2012-12-19 2020-10-28 Affibody AB New polypeptides
MX367423B (es) * 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
LT3038633T (lt) * 2013-08-28 2021-03-25 Ipc Research, Llc Stabilūs polipeptidai, kurie rišasi prie žmogaus komplemento c5

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015819A1 (en) 2001-08-17 2003-02-27 Tanox, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b
WO2007028968A1 (en) 2005-09-09 2007-03-15 Evolutec Limited Method of treating myasthenia gravis
WO2007106585A1 (en) 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement

Also Published As

Publication number Publication date
PH12016500371A1 (en) 2016-05-02
EP3811961B1 (en) 2025-08-20
SA516370622B1 (ar) 2018-12-23
PL3038633T3 (pl) 2021-07-19
UA117933C2 (uk) 2018-10-25
SG11201602679VA (en) 2016-05-30
JP6767865B2 (ja) 2020-10-14
EP3038633B1 (en) 2020-10-14
NZ718153A (en) 2022-05-27
MY173804A (en) 2020-02-24
HUE052613T2 (hu) 2021-05-28
LT3038633T (lt) 2021-03-25
US9994626B2 (en) 2018-06-12
AU2014314222A1 (en) 2016-04-21
BR122023020080A2 (pt) 2023-12-26
CA2926976C (en) 2023-11-28
JP2016529270A (ja) 2016-09-23
CN105658228A (zh) 2016-06-08
HK1225656A1 (en) 2017-09-15
RU2016111115A3 (enExample) 2018-04-25
MX382140B (es) 2025-03-13
CA2926976A1 (en) 2015-03-05
RU2020128977A (ru) 2021-11-30
SI3038633T1 (sl) 2021-05-31
WO2015028558A1 (en) 2015-03-05
PH12016500371B1 (en) 2016-05-02
RS61347B1 (sr) 2021-02-26
JP2020172505A (ja) 2020-10-22
EP3811961A1 (en) 2021-04-28
US20160311870A1 (en) 2016-10-27
DK3038633T3 (da) 2021-01-11
MX2016002397A (es) 2016-09-08
SMT202100006T1 (it) 2021-03-15
KR20160048121A (ko) 2016-05-03
IL244218A (en) 2017-11-30
IL244218A0 (en) 2016-04-21
RU2016111115A (ru) 2017-10-03
CN105658228B (zh) 2020-02-07
RU2733897C2 (ru) 2020-10-09
AU2014314222B2 (en) 2018-05-24
BR112016003142A2 (pt) 2017-10-17
ES2842105T3 (es) 2021-07-12
HRP20210013T1 (hr) 2021-04-02
EP3038633A1 (en) 2016-07-06
PT3038633T (pt) 2021-01-14
CY1123732T1 (el) 2021-10-29

Similar Documents

Publication Publication Date Title
KR102446636B1 (ko) 인간 보체 c5에 결합하는 안정한 폴리펩티드
JP6719438B2 (ja) ヒト補体c5に結合するポリペプチド
EP2231860B1 (en) Polypeptide derived from protein a and able to bind pdgf
KR102345999B1 (ko) Il-1 베타 결합성분
RS63149B1 (sr) Insertabilni varijabilni fragmenti antitela i modifikovani a1-a2 domeni nkg2d liganada
JP7097364B2 (ja) グレムリン-1の結晶構造及び阻害抗体
KR102497083B1 (ko) 돌연변이된 스캐폴드를 갖는 결합 폴리펩티드
WO2017013136A1 (en) Novel binding proteins based on di-ubiquitin muteins and methods for generation
JP2019523016A (ja) 抗体の挿入可能な可変フラグメントおよびnkg2dリガンドの改変型a1−a2ドメイン
CA3212924A1 (en) Multivalent proteins and screening methods
EP4598963A1 (en) Ultrastable antibody fragments with a novel disuldide bridge
HK40050539B (en) Stable polypeptides binding to human complement c5
HK40050539A (en) Stable polypeptides binding to human complement c5
BR112020018563A2 (pt) Anticorpos de domínio único que se ligam à neurotoxina do tétano
HK1225656B (en) Stable polypeptides binding to human complement c5
EP4545554A1 (en) A recombinant polypeptide comprising a metal-binding motif
BR122023020080B1 (pt) Polipeptídeos e compostos de ligação a c5 do complemento humano
CA3268444A1 (en) Ultrastable antibody fragments with a novel disuldide bridge
EP3325515A1 (en) Novel binding proteins based on di-ubiquitin muteins and methods for generation
EP3325514A1 (en) Her2 binding proteins based on di-ubiquitin muteins

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160322

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190828

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201210

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20211220

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220623

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220920

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220921

End annual number: 3

Start annual number: 1

PG1601 Publication of registration